Jonathan M. DeLiberty
University of North Carolina at Chapel Hill(US)Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Pancreatic and Hepatic Oncology Research, Cancer, Hypoxia, and Metabolism, PI3K/AKT/mTOR signaling in cancer, Autophagy in Disease and Therapy, Growth Hormone and Insulin-like Growth Factors
Most-Cited Works
- → Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer(2019)213 cited
- → Functional and biological heterogeneity of KRAS Q61 mutations(2022)41 cited
- → CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment(2021)40 cited
- → Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis(2021)31 cited
- → Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer(2025)10 cited
- → Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain(2022)8 cited
- → Supplementary Table S1 from Atypical KRAS<sup>G12R</sup> Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer(2023)
- → Supplementary Figure from Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors(2023)